The most common question: "I don't have diabetes — can I get Ozempic or Wegovy?" The short answer is yes, with important distinctions. The longer answer involves understanding which drugs are FDA-approved for which indications, the realistic landscape of insurance coverage and cash costs, and an honest risk-benefit assessment for people without metabolic disease who want these drugs for weight loss or other benefits.
The SELECT trial (NEJM, 2023) enrolled 17,604 overweight/obese adults with established cardiovascular disease but WITHOUT diabetes. Semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% over 3+ years — including non-fatal MI, non-fatal stroke, and cardiovascular death. This was a landmark finding: GLP-1 drugs reduce cardiovascular events in non-diabetic obese patients with CVD, independent of their effects on blood sugar.
The important caveat: SELECT required established CVD. For healthy non-diabetic adults without CVD, there is no completed mortality or MACE trial. The cardiovascular benefit is well-established in high-risk populations; extrapolating to low-risk healthy adults requires inference.
| Scenario | Monthly Cost | Notes |
|---|---|---|
| Wegovy / Zepbound with insurance (obesity indication met) | $0–$100 | Prior authorization usually required; formulary varies |
| Wegovy / Zepbound — cash pay brand | $900–$1,400 | Novo Nordisk / Lilly savings cards may reduce to ~$650 for eligible patients |
| Ozempic / Mounjaro with T2D diagnosis + insurance | $0–$150 | Most commercial insurance covers with T2D; Medicare Part D varies |
| Compounded semaglutide (FDA 503B pharmacy) | $150–$400 | Legally available while brand shortage listed; bioequivalence not FDA-verified |
| Compounded tirzepatide | $200–$500 | Same caveat — shortage listing determines legality; sourcing matters critically |
Compounded GLP-1 note: Compounded semaglutide and tirzepatide are legally available from FDA-registered 503B compounding pharmacies while the FDA shortage listing is active. Once manufacturers resolve the shortage and the listing is removed, compounded versions become legally unavailable. Quality varies significantly between compounders — only use FDA-registered 503B facilities, not telehealth companies sourcing from unregulated overseas manufacturers.
Muscle loss: Up to 40% of weight lost on GLP-1 drugs may be lean mass without protein optimization and resistance training. In people with T2D, the metabolic benefits of fat loss outweigh this risk. In healthy non-diabetics, the risk-benefit calculation is more nuanced — see our muscle loss prevention guide. Long-term safety: Most safety data in non-diabetic adults extends 2–3 years from the STEP and SURMOUNT trials. Long-term data beyond 5 years in this population doesn't exist yet. Weight regain: STEP-4 trial showed ~14% weight regain within 1 year of stopping. GLP-1 drugs appear to require ongoing use for sustained weight maintenance — this is a lifetime cost commitment for most users.
Who has the strongest case for GLP-1 drugs without diabetes:
Who should think harder: BMI 25–27, metabolically healthy, no comorbidities, wanting to lose the last 10–15 lbs. The risk-benefit is less clear in this population; the absolute cardiovascular benefit is lower, the muscle loss risk is proportionally larger, and non-drug approaches (resistance training, Zone 2 exercise, protein-optimized diet) remain highly effective.